Pharma Rx brands shift TV spend up 53% after FDA letters
Pharma Rx brands increased their multiscreen TV spending by 53% over six months. This surge followed FDA enforcement letters issued in September targeting deceptive digital drug advertising. The shift indicates a move of advertising spend from digital to TV platforms due to regulatory scrutiny.
Key Takeaways
- Multiscreen TV spend by Pharma Rx brands rose 53% over six months.
- FDA enforcement letters in September targeted deceptive digital drug advertising.
- The spending move suggests budgets shifted from digital channels to TV platforms.
Why It Matters
Pharma Rx brands are redirecting spend quickly in response to FDA scrutiny, with multiscreen TV up 53% over six months after September enforcement letters. That makes TV a more attractive home for drug advertisers than digital placements under regulatory pressure. For the streaming ecosystem, the signal is that multiscreen inventory can absorb category-level budget shifts when compliance risk rises. The next concrete marker to watch is whether the FDA issues additional enforcement letters and whether the multiscreen TV spend figure keeps moving from the September baseline.
Read full article at ppc.land